A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) Given in Combination With an Individualized Rifampin-Resistant Tuberculosis (RR-TB) Therapy in Infants, Children, and Adolescents With RR-TB Disease, Living With or Without HIV
Latest Information Update: 21 May 2024
At a glance
- Drugs Bedaquiline (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Pharmacokinetics
- 16 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 25 Sep 2023 Planned number of patients changed from 72 to 84, Primary endpoints has been amended and trial focus has now shifted to Ar and Pk.
- 25 Sep 2023 Planned End Date changed from 1 Jun 2024 to 15 Aug 2025.